Boston Scientific shares fall after FY26/Q3 guidance outlook cut
Boston Scientific said it is unlikely to meet FY26 and Q3 adjusted EPS and net sales growth guidance after a previously announced cybersecurity incident affected operations.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.